News - Daiichi Sankyo, Effient

Filter

Current filters:

Daiichi SankyoEffient

Popular Filters

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study

14-07-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

Daiichi Sankyo updates on PRASFIT-Elective study, NDA filing

14-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that the follow-up period for the Phase III PRASFIT-Elective…

Asia-PacificAspirinCardio-vascularDaiichi SankyoEffientPharmaceuticalprasugrelRegulationResearch

Anti-clotting drugs prasugrel and clopidogrel yield similar results

27-08-2012

The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Back to top